San Diego, CA – June 10th, 2009 - Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase II clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. AVN-211 was well tolerated and no adverse events were observed in Phase I studies. The compound demonstrated excellent exposure and half-life of more than 15 hours. Avineuro Pharmaceuticals, Inc. will present this data at ICAD 2009 in Vienna, Austria in July.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
